Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk

• Status: Withdrawn
• Trial end date: 2021-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Few studies have reported the efficacy of HCQ in reducing the viral load and improving the severity of symptoms in hospitalized COVID-19 cases with serious respiratory infection. However, the prophylactic benefits of HCQ has not been clearly defined yet.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Texas Cardiac Arrhythmia Research Foundation
• Treatments: Hydroxychloroquine

Criteria

Inclusion Criteria:

• Male or female over 18 years of age at the time of enrollment

• COVID-19 test positive patients with mild-moderate symptoms including fever >37.50 F

• Consecutive consenting staff at ICU, ER and COVID-19 unit that have never been diagnosed with COVID-19

Exclusion Criteria:

• Exclusion criteria:

• Hepatic cirrhosis or active hepatitis B or C

• Severe renal disease

• Hospitalized for severe symptoms of COVID-19 (ARDS), on mechanical ventilation or ECMO

• Contraindication to HCQ

• Using HCQ for some other condition (i.e. SLE, rheumatoid arthritis)

• Pregnant or breast feeding

• Known history of long QT syndrome (QTc >500 ms on electrocardiogram)

• Seizure disorder

• Body weight <50kg

• Psoriasis

• Unwilling to provide informed consent